surpass cvot tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide

Such studies remind us that negative or nuanced outcomes are often the most enlightening, pushing the field forward and helping refine both scientific questions and clinical practice

Cycling is typical, not continuous use Most protocols cycle 3-6 months on, followed by an off period

Semaglutide: GLP-1 receptor agonistit slows gastric emptying and helps you feel full faster, which curbs overeating

On the parasitoids side, the ways of targeting the host immune compartments are diverse and the identification of molecular mechanisms remains a major challenge

Perhaps nowhere is this tension more apparent than in the case of chronic kidney disease (CKD)a condition that is currently difficult to treat, typically leading to dialysis, transplant, or even death

Semaglutide in managing fibromyalgia pain: Mechanisms and clinical outcomes